Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.

The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.

Zhitong FinanceDec 25 21:48 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET

BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"

BenzingaDec 23 06:06 ET

Express News | Beigene - Will Change Its Nasdaq Ticker Symbol for Its American Depositary Shares From "Bgne" to "Onc" on Jan 2, 2025

ReutersDec 23 06:05 ET

BEIGENE (688235.SH): Plans to change the company's Nasdaq stock code to "ONC".

Gelonghui, December 23rd ┃ BEIGENE (688235.SH) announced that the company's American depositary shares traded on Nasdaq will change their stock code from "BGNE" to "ONC," effective from January 2, 2025, to emphasize the company's firm commitment to providing innovative oncology drugs globally. The stock code and abbreviated name on the Shanghai Stock Exchange and the stock code and abbreviated name on the Hong Kong Stock Exchange will remain unchanged. The change of the Nasdaq stock code can be implemented without submission for discussion at the company’s shareholder meeting.

Gelonghui FinanceDec 23 06:03 ET

BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireDec 23 06:00 ET